Regulatory and Exhausted T Cell Responses to AAV Capsid
Gene Therapy Center; Department of Pediatrics, Division of Pediatric Pulmonology
Genetics and Genomics | Immunity | Immunoprophylaxis and Therapy | Therapeutics
Recombinant adeno-associated viruses (AAVs) are quickly becoming the preferred viral vector for viral gene delivery for the treatment of a wide variety of genetic disorders. However, since their use in a clinical trial targeting hemophilia B patients 10 years ago, immune responses to the AAV capsid appear to have hampered some of the early clinical gene transfer efficacy. Indeed, AAV-based gene transfer has been shown to reactivate capsid-specific memory T cells, which have correlated with a decline in AAV-transduced tissue in some patients. Importantly, clinical trials have also shown that this reactivation can be quelled by administering time-course taper of glucocorticoid steroids before or after dosing. More recently, two clinical studies have shown that AAV gene transfer is not only able to induce a deleterious immune response, but also can result in the initiation of a tolerance to the AAV capsid mediated by regulatory T cells and exhausted T cells. This article reviews clinical trials describing immune responses to AAV, as well as the mechanisms responsible for immune tolerance in chronic infections and how it could apply to AAV-based gene transfer. A better understanding of both cytotoxic and tolerogenic immune responses to recombinant AAV will lead to safer gene transfer protocols in patients.
AAV, CTL, T cell exhaustion, Treg, immune response, regulatory T cell
Rights and Permissions
Citation: Hum Gene Ther. 2017 Apr;28(4):338-349. doi: 10.1089/hum.2017.022. Link to article on publisher's site
Human gene therapy
Gernoux, Gwladys; Wilson, James M.; and Mueller, Christian, "Regulatory and Exhausted T Cell Responses to AAV Capsid" (2017). University of Massachusetts Medical School Faculty Publications. 1297.